365 related articles for article (PubMed ID: 27983998)
1. Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia.
Chang PY; Tsao SM; Chang JH; Chien MH; Hung WY; Huang YW; Yang SF
Clin Chim Acta; 2016 Dec; 463():174-180. PubMed ID: 27983998
[TBL] [Abstract][Full Text] [Related]
2. Plasma long pentraxin 3 (PTX3) concentration is a novel marker of disease activity in patients with community-acquired pneumonia.
Kao SJ; Yang HW; Tsao SM; Cheng CW; Bien MY; Yu MC; Bai KJ; Yang SF; Chien MH
Clin Chem Lab Med; 2013 Apr; 51(4):907-13. PubMed ID: 23152412
[TBL] [Abstract][Full Text] [Related]
3. Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia.
Kao SJ; Chuang CY; Tang CH; Lin CH; Bien MY; Yu MC; Bai KJ; Yang SF; Chien MH
Clin Chem Lab Med; 2014 Mar; 52(3):445-51. PubMed ID: 24108208
[TBL] [Abstract][Full Text] [Related]
4. Plasma Monocyte Chemoattractant Protein-1 Level as a Predictor of the Severity of Community-Acquired Pneumonia.
Yong KK; Chang JH; Chien MH; Tsao SM; Yu MC; Bai KJ; Tsao TC; Yang SF
Int J Mol Sci; 2016 Jan; 17(2):. PubMed ID: 26840299
[TBL] [Abstract][Full Text] [Related]
5. Utility of Plasma Osteopontin Levels in Management of Community-Acquired Pneumonia.
Chang JH; Hung WY; Bai KJ; Yang SF; Chien MH
Int J Med Sci; 2016; 13(9):673-9. PubMed ID: 27647996
[TBL] [Abstract][Full Text] [Related]
6. Circulating level of high mobility group box‑1 predicts the severity of community‑acquired pneumonia: Regulation of inflammatory responses via the c‑Jun N‑terminal signaling pathway in macrophages.
Wang HL; Tsao SM; Yeh CB; Chou YE; Yang SF
Mol Med Rep; 2017 Sep; 16(3):2361-2366. PubMed ID: 28677786
[TBL] [Abstract][Full Text] [Related]
7. Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia.
Yeh YH; Chang JL; Hsiao PC; Tsao SM; Lin CH; Kao SJ; Chou MC; Yang SF; Chien MH
J Clin Lab Anal; 2013 Jul; 27(4):253-60. PubMed ID: 23852780
[TBL] [Abstract][Full Text] [Related]
8. [Immunocompetent adults hospitalized for a community-acquired pneumonia: Serum C-reactive protein as a prognostic marker].
Saldías-Peñafiel F; Salinas-Rossel G; Farcas-Oksenberg K; Reyes-Sánchez A; Díaz-Patiño O
Rev Med Chil; 2019 Aug; 147(8):983-992. PubMed ID: 31859962
[TBL] [Abstract][Full Text] [Related]
9. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
10. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.
Chiang TY; Yu YL; Lin CW; Tsao SM; Yang SF; Yeh CB
Clin Chim Acta; 2013 Sep; 424():261-6. PubMed ID: 23792071
[TBL] [Abstract][Full Text] [Related]
11. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
[TBL] [Abstract][Full Text] [Related]
12. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia.
Lee YT; Chen SC; Shyu LY; Lee MC; Wu TC; Tsao SM; Yang SF
Clin Chim Acta; 2012 Mar; 413(5-6):630-5. PubMed ID: 22209964
[TBL] [Abstract][Full Text] [Related]
13. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
14. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia.
Spoorenberg SM; Vestjens SM; Rijkers GT; Meek B; van Moorsel CH; Grutters JC; Bos WJ;
Respirology; 2017 Apr; 22(3):542-550. PubMed ID: 27782361
[TBL] [Abstract][Full Text] [Related]
15. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children.
Wrotek A; Jackowska T; Pawlik K
Adv Exp Med Biol; 2015; 835():1-7. PubMed ID: 25315615
[TBL] [Abstract][Full Text] [Related]
16. Elevated plasma stromal-cell-derived factor-1 protein levels correlate with severity in patients with community-acquired pneumonia.
Tsai PK; Hsieh MJ; Wang HL; Chou MC; Yang SF; Yeh CB
Dis Markers; 2014; 2014():829706. PubMed ID: 25371597
[TBL] [Abstract][Full Text] [Related]
17. The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study.
Ito A; Ito I; Inoue D; Marumo S; Ueda T; Nakagawa H; Taki M; Nakagawa A; Tatsumi S; Nishimura T; Shiota T; Ishida T
Int J Infect Dis; 2020 Mar; 92():228-233. PubMed ID: 31981766
[TBL] [Abstract][Full Text] [Related]
18. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
19. Improved management of community-acquired pneumonia in the emergency department.
Julián-Jiménez A; Palomo de los Reyes MJ; Parejo Miguez R; Laín-Terés N; Cuena-Boy R; Lozano-Ancín A
Arch Bronconeumol; 2013 Jun; 49(6):230-40. PubMed ID: 23477946
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of plasma neutrophil gelatinase-associated lipocalin concentration for predicting the severity and mortality of patients with community-acquired pneumonia.
Kim JW; Hong DY; Lee KR; Kim SY; Baek KJ; Park SO
Clin Chim Acta; 2016 Nov; 462():140-145. PubMed ID: 27662812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
